Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2)
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
|Official Title:||CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL|
- Stroke and death [ Time Frame: 4 years ]The primary outcome is the composite of stroke plus death within 44 days after randomization and ipsilateral stroke thereafter up to 4 years.
- Cognitive Function [ Time Frame: 4 years ]The assess if MEDICAL management differs from CAS, and differs from CEA, to maintain the level of cognitive function at the 4-year assessment.
- Major Stroke [ Time Frame: 4 years ]if there are treatment differences in the incidence of major stroke at 4-years among all arms of the study
- Effect modification [ Time Frame: 4 years ]Potential effect modification of the CAS or CEA versus MEDICAL differences, based on patient age, sex, severity of carotid stenosis, restenosis, risk factor level, and duration of asymptomatic period.
|Study Start Date:||December 2014|
|Estimated Primary Completion Date:||December 2020 (Final data collection date for primary outcome measure)|
Active Comparator: Carotid Endarterectomy (CEA)
|Procedure: Carotid endarterectomy|
Active Comparator: Carotid Stenting (CAS)
|Device: Carotid stenting|
No Intervention: Medical
Intensive medical management
Prevention of stroke involves managing and treating risk factors. Most strokes are caused when blood flow to a portion of the brain is blocked. One place this often happens is in the carotid artery. This blockage is called atherosclerosis or hardening of the arteries.
The purpose of this trial is to determine the best way to prevent strokes in people who have a high amount of blockage of their carotid artery but no stroke symptoms related to that blockage. Each eligible participant will be evaluated to determine which procedure(s) is best for him/her. All participants will receive intensive medical treatment. In addition, participants will be randomized to receive the selected procedure or not.
The trial will be conducted in the United States and Canada by physicians carefully selected on their ability to perform the procedures at low risk. Another key component of the trial is that important stroke risk factors, including hypertension, diabetes, high cholesterol, cigarette smoking, physical activity, and diet will be managed intensively. Participants will remain in the study for 4 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02089217
|Contact: CREST-2 Administrative Center||844-956-1826|
Show 127 Study Locations
|Principal Investigator:||Thomas G. Brott, MD||Mayo Clinic Florida|
|Principal Investigator:||James F. Meschia, MD||Mayo Clinic Florida|
|Principal Investigator:||Brajesh K. Lal, MD||University of Maryland|
|Principal Investigator:||George Howard, DrPH||University of Alabama at Birmingham|